Page last updated: 2024-08-21

vancomycin and op-1118

vancomycin has been researched along with op-1118 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Babakhani, F; Gomez, A; Robert, N; Sears, P1
Crook, DW; Louie, TJ; Miller, MA; Sears, P; Weiss, K1
Babakhani, F; Citron, DM; Goldstein, EJ1
Babakhani, F; Bouillaut, L; Gomez, A; Nguyen, L; Sears, P; Sonenshein, AL1
Allen, CA; Babakhani, F; Nguyen, L; Sears, P; Sorg, JA1
Babakhani, F; Bouillaut, L; Gomez, A; Sears, P; Sims, C; Sonenshein, AL1
Chen, X; Cheng, M; Hing, TC; Ho, S; Ichikawa, Y; Kelly, CP; Koon, HW; Pothoulakis, C1

Trials

1 trial(s) available for vancomycin and op-1118

ArticleYear
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2

    Topics: Administration, Oral; Aged; Aminoglycosides; Anti-Bacterial Agents; Chromatography, Liquid; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Feces; Female; Fidaxomicin; Humans; Male; Middle Aged; Severity of Illness Index; Tandem Mass Spectrometry; Treatment Outcome; Vancomycin

2012

Other Studies

6 other study(ies) available for vancomycin and op-1118

ArticleYear
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
    Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 8

    Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Bacterial; Fidaxomicin; Microbial Sensitivity Tests; Time Factors; Vancomycin

2011
Antimicrobial activities of fidaxomicin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2

    Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials as Topic; Clostridioides difficile; Clostridium Infections; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Feces; Fidaxomicin; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Recurrence; Vancomycin

2012
Fidaxomicin inhibits spore production in Clostridium difficile.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2

    Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Load; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Gene Expression Regulation, Bacterial; Genes, Bacterial; Metronidazole; Microbial Sensitivity Tests; Rifamycins; Rifaximin; Spores, Bacterial; Vancomycin

2012
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:1

    Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Culture Media; Fidaxomicin; Microbial Sensitivity Tests; Spores, Bacterial; Taurocholic Acid; Vancomycin

2013
Fidaxomicin inhibits toxin production in Clostridium difficile.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:3

    Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Culture Media; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Fidaxomicin; Gene Expression; Gene Expression Profiling; Humans; Metronidazole; Vancomycin

2013
Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8

    Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Toxins; Clostridioides difficile; Edema; Enterocolitis, Pseudomembranous; Enterotoxins; Epithelial Cells; Fibroblasts; Fidaxomicin; Gene Expression; Ileum; Injections, Intralesional; Interleukin-1beta; Intestinal Mucosa; Male; Metronidazole; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; RNA, Messenger; Vancomycin

2014